EZElena S. Zubova

Elena S. Zubova

*This is an algorithmically generated author record based on publicly available information.

Elena S. Zubova has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Domestic Tetravaccine (Measles-Rubella-Mumps) – Immunization of Premature Babies

    by V. V. Semerikov, N. O. Postanogova, L. V. Sofronova, E. S. Zubova, A. Yu. Musikhina, O. A. Perminova, М. А. Permiakova

    Relevance. According to WHO experts, in the world every year more than 10% of children (about 15 million) are born prematurely. Premature births have a high risk of adverse course of infectious diseases, including vaccine-preventable diseases due to insufficient maternal antibodies, active transmission of which occurs in the third semester of pregnancy. Aim. To study the tolerability of Vactrivir® vaccine in infants born prematurely. Materials and methods. The children (mean age 1.7 ± 0.6 years, born prematurely with a body weight of less than 2500 g) included in the study group participated in the study. The control group consisted of years born at term and comparable in sex and age with the children in the study group. Results. The administration of Vaktrivir® vaccine to infants born prematurely confirmed the high safety profile of the drug. There were no deviations from the norm in general and biochemical blood tests, general urinalysis, and the content of immunoglobulins IgA, IgM, IgG, IgE in the dynamics. There were no undesirable side effects in the postvaccination period, which confirms good tolerability of the drug. Conclusion. In practice, the high safety profile and good tolerability of the domestic tetravaccine Vaktrivir® for immunization of premature infants have been confirmed.


  • Vaccine prophylaxis of pneumococcal infection among premature infants with bronchopulmonary dysplasia

    by Владислав Семериков, Елена Зубова, Фгбоу Во Пгму Им. Академика Е. А. Вагнера Минздрава России, Вера Лошкарева, Людмила Софронова, Мария Пермякова

    Introduction. Bronchopulmonary dysplasia (BPD) is the most common chronic lung disease among children of the first year of life, especially children born prematurely with extremely low and very low body weight. Material and methods. To estimate the number of children born alive in Perm Territory between 2015 and 2017, official statistics data were used. Experimental epidemiological studies were used to assess safety, reactogenicity, immunogenic activity and preventive efficacy of the Prevnar 13 vaccine when immunizing preterm infants with bronchopulmonary dysplasia under prospective controlled randomized clinical observation. Results. There were 29 premature infants with bronchopulmonary dysplasia under observation, the control group comprised 29 unvaccinated premature infants with BPD and 30 full-term infants. The PCV 13 vaccination of preterm infants with BPD established good tolerance, poor reactogenicity (17.2±0.57%) and vaccine tolerance like full-term infants (16.5±0.55%), high safety profile, high immunogenic properties (seroconversion – 93.1%, seroconversion factor – 5.5). Evaluation of immunogenic activity among children with BPD vaccinated with the PCV 13 vaccine revealed high immunological efficacy compared to unvaccinated healthy children. Conclusion. The need for vaccination of premature babies with BDL against pneumococcal infection has been scientifically substantiated. The study has confirmed safety, poor reactogenicity, high immunogenic activity and preventive efficacy of the Prevenar 13 vaccine among premature babies with BDL under the conditions of the catamnesis department of the perinatal center within the follow-up monitoring of vaccinated infants over three years. Introduction. Bronchopulmonary dysplasia (BPD) is the most common chronic lung disease among children of the first year of life, especially children born prematurely with extremely low and very low body weight. Material and methods. To estimate the number of children born alive in Perm Territory between 2015 and 2017, official statistics data were used. Experimental epidemiological studies were used to assess safety, reactogenicity, immunogenic activity and preventive efficacy of the Prevnar 13 vaccine when immunizing preterm infants with bronchopulmonary dysplasia under prospective controlled randomized clinical observation. Results. There were 29 premature infants with bronchopulmonary dysplasia under observation, the control group comprised 29 unvaccinated premature infants with BPD and 30 full-term infants. The PCV 13 vaccination of preterm infants with BPD established good tolerance, poor reactogenicity (17.2±0.57%) and vaccine tolerance like full-term infants (16.5±0.55%), high safety profile, high immunogenic properties (seroconversion – 93.1%, seroconversion factor – 5.5). Evaluation of immunogenic activity among children with BPD vaccinated with the PCV 13 vaccine revealed high immunological efficacy compared to unvaccinated healthy children. Conclusion. The need for vaccination of premature babies with BDL against pneumococcal infection has been scientifically substantiated. The study has confirmed safety, poor reactogenicity, high immunogenic activity and preventive efficacy of the Prevenar 13 vaccine among premature babies with BDL under the conditions of the catamnesis department of the perinatal center within the follow-up monitoring of vaccinated infants over three years.

  • Open Access

    Bronchopulmonary Pathology Prevalence Among Premature infants and Estimation of Prophylactic Efficacy and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Premature infants with Bronchopulmonary Dysplasia

    by Vladislav V. Semerikov, Elena S. Zubova, Vera L. Loshkareva, Lyudmila V. Sofronova, Mariya A. Permyakova

    Background. The most frequent chronic lung pathology among infants and especially in premature children with extremely low and very low body weight is bronchopulmonary dysplasia (BPD). The aim of the study is to study the prevalence of bronchopulmonary pathology among premature children and justify the need to vaccinate against pneumococcal disease premature children suffering from BPD. Methods. The official statistics (Form №32) and data from annual reports of the catamnesis department of “the Honourary order” Perm Regional Clinical Hospital were used in order to measure the number of premature children born alive in Perm region in 2015-2017 yy. The estimation of prophylactic efficacy and reactogenicity of 13-valent pneumococcal conjugate vaccine (PCV13) at immunization of premature children with BPD. Results. The study group included vaccinated premature children with BPD (n=29), the experimental group included non-vaccinated premature children with BPD (n=29) and 30 vaccinated term children. Administration of PCV13 in premature children suffering from BPD has revealed its high prophylactic efficacy (no cases of community-acquired pneumonia among vaccinated children during the prospective study for 3 years), high tolerability (no cases of broncho-obstructive syndrome or negative effects on respiratory system such as apnoea or desaturation among vaccinated children). Low reactogenicity (17.2 ± 0.57%) and similar vaccine tolerance with term children (16.5 ± 0.55%) has been revealed as well. The combination of PCV13 with other vaccines from immunisation schedule did not increase the number of vaccine-induced diseases in comparison with administration of PCV13 alone. Conclusion. The scientific necessity of vaccination of premature children with BPD against pneumococcal disease has been proved. The high prophylactic efficacy and low reactogenicity of PCV13 in this children group at tertiary neonatological care (catamnesis department of perinatal center) has been established within the national immunisation schedule.


  • Multicenter study of serotype distribution of Streptococcus pneumoniae nasopharyngeal isolates from healthy children in the Russian Federation after introduction of PCV13 into the National Vaccination Calendar

    by Sergey Sidorenko, Wolfgang Rennert, Yuri Lobzin, Nikolay Briko, Roman Kozlov, Leila Namazova-Baranova, Irina Tsvetkova, Vladimir Ageevets, Ekaterina Nikitina, Anastasia Ardysheva, et al.


  • Open Access

    Practical experience of using pneumococcal thirteen-valent conjugate vaccine among premature infants

    by Elena S. Zubova, Vadislav V. Semerikov, Ludmila V. Sofronova, Зубова Елена Сергеевна, Семериков Вадислав Васильевич, Софронова Людмила Васильевна

    Aim. To ground the necessity of premature infants vaccination against pneumococcal infection and estimate the reactogenicity and immune activity of pneumococcal 13-valent conjugate vaccine when vaccinating infants with different degree of prematurity. Materials and methods. The clinical study enclosed 88 children including 16 (18.2 0.25 %) infants with extremely low birth body mass (ELBM) and 28 infants (31.8 0.32 %) with very low body mass (VLBM). The mean gestation age was 31 0.41 weeks. The mean birth weight was 1530 66.58 grams. Bronchopulmonary dysplasia was diagnosed in 27 0.25 % of infants. Thirty one infants underwent assessment of the concentration of the total level of specific blood serum IgG antibodies to S. Pneumonia antigens contained in vaccine. The mean age of these infants was 9.71 0.74 months, the mean gestation age at birth 30 0.41 weeks (25 to 41 weeks). The mean birth weight 1441 66.58 grams, ELBM 14 infants, VLBM 18 infants. Results. The mild general postvaccinal reactions were noted in 11.3 1.24% of infants, which were arrested for 2 days with no drugs used. The moderate and severe reactions were observed in 2.27 0.62 % of infants. No local postvaccinal reactions were registered. When studying the concentration of the total level of specific IgG antibodies to S. Pneumonia antigens, there was revealed a more than 4- fold increase in geometric mean of pneumococcal antibody titer that proves a high immunogenicity of this vaccine in premature infants. A high level of pneumococcal antibodies after vaccination was reached in 24 infants (75 1.24 % of infants). Conclusion. The necessity of immunization of premature infants against pneumococcal infection was scientifically grounded. The application of conjugate 13-valent pneumococcal vaccine among premature infants confirmed a high profile of its safety and high immunogenicity. Improvement of communicative habits between parents and medical personnel regarding the necessity of vaccination of premature infants against pneumococcal infection, as an advanced technology, will permit to provide a timely coverage of infants with immunization (98 %).

  • Open Access

    The Effect of Selective and Mass Immunization Against Pneumococcal Infection on the Morbidity and Mortality due to Community-Acquired Pneumonia in Children Under 5 Years of Age

    by Vadislav V. Semerikov, Elena S. Zubova, Lyudmila V. Sofronova

    Background. It is required to perform estimation of epidemiological and cost efficacy (regarding morbidity rate) of mass routine vaccination against pneumococcal infection in Russian children and carried out earlier selective vaccination of children from high-risk groups on the basis of four-year experience. It is also important to estimate the rate of hospital admissions in this patient group, long-term and annual cycles, morbidity age and etiology structure, and mortality due to community-acquired pneumonia as one of the most common form of pneumococcal disease.The aimis to study the effect of selective and mass immunization against pneumococcal infection on the morbidity and mortality due to community-acquired pneumonia in children under 5 years of age. Methods.The analysis of communityacquired pneumonia morbidity (in 2003–2018) and mortality due to pneumonias (in 2003–2018) in children under the 14 years old in Perm was carried out. Serotypes of circulating pneumococcus, etiology of community-acquired pneumonias and immunization cost efficacy (direct expense on health care) were further studied. The analysis of study indexes was carried out following selective (vaccination of at-risk children in 2011–2014) and mass (vaccination of infants in 2015–2018) immunization strategies. Results. The morbidity rate of community-acquired pneumonias decreased by 4.0 times (from 267.0 to 66.7 for 1000) after performing selective vaccination (2011–2014) in at-risk children (frequently and chronically ill children). The morbidity rate of community-acquired pneumonias in non vaccinated children of the same group increased by 2.0 times (from 40.0 to 80.0 for 1000 non-vaccinated). The prophylactic efficacy index was 46.0. Whereby the antibacterial index among vaccinated frequently and chronically ill children was 0.11 on one child. This index has decreased by 2.6 times (from 0.11 to 0.04 on one child) in a year within the framework of prospective controlled randomized clinical study. The antibacterial index among non-vaccinated children of this group remained slightly the same: 0.09 and 0.12 respectively. During the selective vaccination the mortality rate among infants decreased by 2 times: long-term average index was 17.9 (2011–2014) against 35.2 (2003-2010) on 100 thousand children. Mass vaccination of infants against pneumococcal infection has reduced the incidence of community-acquired pneumonias among children under 2 years of age and has led to absence of multiple sites of pneumococcal infection in children’s organizations. It also has reduced the number of hospitalized children and achieved zero mortality due to pneumonias in infants by the third year of this immunization strategy implementation. The obtained results were achieved mainly due to circulation of 7 pneumococcal serotypes (6A, 6B, 9V, 14, 19A, 19F, 23F) in children under 5 years of age. The threshold level of vaccination against pneumococcal infection advancing morbidity and mortality due to pneumonias in children was specified. The strategy of mass vaccination of infants was cost-effective. Conclusion. The new data on epidemiological and cost efficacy of various immunization strategies against pneumococcal infection in children was obtained.


  • Open Access

    Epidemiological and economic efficiency of mass vaccinal prevention against pneumococcal infection in children compared with selective immunization at the example of community-acquired pneumonia

    by Vadislav V. Semerikov, Elena S. Zubova, Lyudmila V. Sofronova

    Aim. To study the epidemiological pattern of community-acquired pneumonias in children and the influence of mass vaccinal prevention on morbidity and mortality. Materials and methods. Vaccination of children against pneumococcal infection on the territory of a large industrial center of Western Urals was analyzed, influence of mass vaccination against pneumococcal infection on pneumonia morbidity and mortality in children was determined. Results. Mass vaccinal prevention of children of the first year of life against pneumococcal infection (vaccination volume 102 353.6 per 100 thousand children under 6) significantly influenced morbidity level regarding community-acquired pneumonias in the group of vaccinated children under 2 (1619.9 0.78 versus 15233.7 2.5 per 100 thousand in the group of unvaccinated, odds ratio and its confidence interval was 9.40 [95 % CI 8.4610.44]), on community-acquired streptococcal morbidity of children under 6 (r = 0.97; regression coefficient = 36.30, р 0.001; R2 = 91.0 %, significance F = 0.01 and possibility 95.0 %) and 5-fold decreased the mortality level (from 35.2 before vaccination started to 6.8 per 100 thousand) till its full absence in the third year of realization of this strategy. No analogous influence on the main manifestations of epidemiological process of community-acquired pneumonia was noted in case of selective immunization against pneumococcal infection among 25 year olds, belonging to high risk groups (vaccination volume 10 417.08 per 100 thousand children under 6). Conclusions. The strategy of mass vaccination of children of the first year of life was characterized by the greatest epidemiological and economic benefits. Economic efficiency taking into account vaccination costs in terms of 1000 of vaccinated children was 17.1 times higher and was equal to 8.3656 mln rub per 1000 inhabitants versus 0.4890 mln rub in case of selective immunization of high risk group children.


  • Open Access

    THE EXPERIENCE OF THE USE OF PNEUMOCOCCAL CONJUGATE VACCINE IN YOUNG CHILDREN IN THE PERM KRAI

    by E. S. Zubova, V. V Semerikov, L. V Sofronova

    A comparative evaluation of the reactogenicity and preventive efficacy of the use of Prevnar Pneumococcal 7-valent conjugate vaccine in healthy (N=95) and frequently ill children (N=30) has been performed. Under administration Vaccine was characterized by low reactogenicity and high prevention efficacy. Index of prophylactic efficacy among long-term and frequently ill children was 46.0 that’s 6 times higher than among healthy vaccinated children - 7.55.